Trastuzumab deruxtecan (Enhertu®). HTA ID: 22050

Assessment Status NCPE Assessment Process Complete
HTA ID 22050
Drug Trastuzumab deruxtecan
Brand Enhertu®
Indication As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
Assessment Process
Rapid review commissioned 11/07/2022
Rapid review completed 27/07/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/08/2022
Pre-submission consultation with Applicant 25/10/2022
Full submission received from Applicant 09/03/2023
Preliminary review sent to Applicant 15/09/2023
NCPE assessment re-commenced 13/10/2023
Factual accuracy sent to Applicant 23/11/2023
NCPE assessment re-commenced 30/11/2023
NCPE assessment completed 12/12/2023
NCPE assessment outcome The NCPE recommends that trastuzumab deruxtecan (Enhertu®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary.

Plain English Summary

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.